Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | OTC | P00480 | 1/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19748369 | 1.00 | DPP7 (0.33) | DPP7SIRT5GNAI3GNAO1GNAI1 | |
| SCHEMBL19744548 | 0.79 | DPP7 (0.39) | DPP7SIRT5GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL19745098 | 0.78 | DPP7 (0.38) | DPP7SIRT5GNAI3GNAO1GNAI1 | |
| SCHEMBL14739594 | 0.77 | SIRT5 (0.46) | SIRT5FOLH1SIRT6SIRT1 | |
| SCHEMBL20168409 | 0.77 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1OTC | |
| SCHEMBL20168406 | 0.77 | DPP7 (0.46) | DPP7GNAI3GNAO1GNAI1OTC | |
| SCHEMBL19746069 | 0.77 | CYP2D6 (0.40) | — | |
| SCHEMBL19744749 | 0.75 | FOLH1 (0.31) | FOLH1 | |
| SCHEMBL19744753 | 0.75 | FOLH1 (0.31) | FOLH1 | |
| Benzene SCHEMBL28286275 | 0.73 | DPP7 (0.37) | DPP7GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472130-B1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2022-02-16 | — | — | EP | disclosed |
| US-10730832-B2 | Aliphatic prolinamide derivatives | Orion Ophthalmology LLC (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | Orion Ophthalmology LLC (US) | 2019-10-31 | — | — | US | disclosed |
| EP-3472130-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | ORION OPTHALMOLOGY LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017222917-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | INCEPTION 4, INC. (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10730832-B2 | Aliphatic prolinamide derivatives | HTRA1, ALDH1A2, PREP | DPP7 49/4885SIRT5 1952/4885GNAI3 2567/4885 |
| US-20190330146-A1 | ALIPHATIC PROLINAMIDE DERIVATIVES | HTRA1, ALDH1A2, PREP | DPP7 49/4885SIRT5 1952/4885GNAI3 2567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.